Eisai Inc.
NEWS
The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval.
It’s hard to say if it was actually a wild ride after the release of Alzheimer’s data, but Biogen shares dropped from $383.83 to $340.84 at the news, although it appears to be rebounding slightly.
Many analysts and investors were holding their breaths, waiting to see what Biogen would say at yesterday’s second-quarter financial report. The financials weren’t the focus, however, but what the Cambridge, Massachusetts biotech had to say about its pipeline, especially for Alzheimer’s disease, was.
According to a new study published in Neurology, researchers discovered increased biomarkers for Alzheimer’s in the brains of older patients with high blood pressure.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.
Every year for the last 32 years, Enrst & Young has awarded entrepreneurs in various categories, including Life Science, Consumer Products and Retail, Distribution and Manufacturing and other categories. The awards are given in June. The finalists have been announced. Here’s a look at some of the finalists and semi-finalists.
The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer.
JOBS
IN THE PRESS